Injectable Tirzepatide

Tirzepatide is a dual GIP and GLP-1 receptor agonist. This product is a compounded injectable Tirzepatide formulation. Compounded Tirzepatide is not FDA-approved, and FDA has not reviewed this formulation or route of administration for safety, effectiveness, quality, or bioavailability. A licensed healthcare provider will determine whether a compounded formulation is medically necessary and appropriate for you.

Tirzepatide acts on GIP and GLP-1 receptors, which help regulate blood sugar and appetite by supporting insulin release, slowing digestion, and may help with feelings of fullness. The absorption, systemic exposure, and clinical effects of compounded Tirzepatide have not been evaluated or approved by the FDA.

Compounded injectable Tirzepatide: Most people will use their injectable Tirzepatide once weekly. Carefully follow the instructions on your prescription and inject only the exact dose prescribed to you. If you have any questions about your dosage or how to administer your injection, please contact your healthcare provider or pharmacy.

Individual responses to compounded Tirzepatide vary. Some people may begin noticing changes in appetite within the first few weeks,* while for others, the effects build more gradually as their provider adjusts the dose. Compounded Tirzepatide is an unapproved medication, and its rate of absorption, timing, and overall clinical response have not been evaluated or established by the FDA. If you are not experiencing the expected response, please contact your healthcare provider.

Injectable compounded Tirzepatide is typically administered once a week, on the same day each week, at any time of day, with or without food. Always administer the exact dosage prescribed by your healthcare provider. Do not take additional doses, skip doses, or change your injection day without consulting your provider first.

Tell your provider about all medical conditions and medications you take before starting treatment. This is particularly important if you have had medullary thyroid carcinoma (MTC), or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2); a history of pancreatitis, gallbladder disease, kidney problems, severe gastrointestinal disease or gastroparesis, diabetes or diabetic retinopathy; or if you use insulin or medications that may lower blood sugar. Tell your provider if you are pregnant, planning pregnancy, breastfeeding, or use oral hormonal contraception. The safety profile of compounded injectable Tirzepatide has not been established through FDA review.

Do not use other Tirzepatide-containing products or GLP-1 receptor agonists unless specifically directed by your provider. Tell your provider about all prescription medications, over-the-counter medications, vitamins, and supplements you take. Avoid high-fat foods, foods with lots of added sugar, trans and saturated fats, processed carbohydrates, and foods with high sodium as they may cause intestinal discomfort. Tirzepatide can slow gastric emptying, which may affect the absorption of other oral medications. It is not known whether the same effect occurs to the same extent with compounded injectable Tirzepatide.

The most common side effects of Tirzepatide involve your digestion and gastrointestinal tract. Nausea, diarrhea, vomiting, constipation, dyspepsia, abdominal pain, fatigue, injection site reactions, hypersensitivity reactions, burping, hair loss, and gastroesophageal reflux disease (GERD) may occur. Other common side effects may include headache, dizziness, tiredness, and low blood sugar levels in people who have diabetes. Because compounded injectable Tirzepatide has not been FDA-approved or evaluated for safety, effectiveness, quality, or bioavailability, its adverse-effect profile and frequency of side effects are not established. Contact us if you experience persistent or concerning symptoms. For a full list of the possible side effects of Tirzepatide, including the less common but more serious side effects, look at the patient safety information on our website and the Tirzepatide package information.